Partnership combines additive manufacturing technology with product application to offer EBM-designed, -manufactured medical implants.
Arcam AB officials have signed a strategic alliance agreement with DiSanto Technology Inc., Shelton, CT, in order to offer customers, including industry-leading orthopedic and spinal implant companies, comprehensive product application development and manufacturing of EBM-based implants and other components.
By offering the combined capabilities of both organizations to each of their existing and new customers, the strategic alliance shall serve to accelerate market adoption and penetration of commercially manufactured, finished EBM-based implants and components. The strategic partnership will leverage Arcam’s EBM technology with DTI’s expertise in engineering and producing finished components.
As part of the strategic alliance agreement, Arcam will support the expansion, equipping and operation of DTI’s manufacturing capability of finished parts made with Arcam’s EBM technology. The strategic alliance agreement calls for DTI to initially purchase two EBM systems to be delivered and installed at DTI.
“This partnership with DTI is an important strategic step for Arcam. Our EBM technology has been used for manufacturing of implants in Europe since 2007, and in the US since 2010. To date some 30 000 orthopedic implants manufactured with EBM technology have been implanted worldwide. Arcam has many customers that have purchased EBM systems to develop and manufacture EBM-based product applications. Through this alliance with DTI, we will now also be able to offer existing and new customers contract manufacturing capabilities and help them commercialize new product applications. This will in turn give our customers the opportunity to more quickly and more efficiently develop products and get them to the market,” says Magnus René, CEO, Arcam.
“We are very pleased to be the manufacturing partner of Arcam. We are excited about incorporating Arcam’s proprietary EBM technology into our manufacturing capability offering to our existing and new customers. This will enable us to help such customers in rapidly developing product applications and to commercially produce such products for them with Arcam’s cost-efficient, regulatory-cleared Additive Manufacturing technology,” says Ron Dunn, CEO, DiSanto Technology Ltd.
In connection with the strategic alliance agreement, Arcam will provide capital to and arrange financing for DTI to support its EBM-based manufacturing capability.
The securities underlying the financing provide for potential minority cross-ownership positions in each other. Furthermore, as part of the strategic alliance, Arcam has an option to acquire DTI in its entirety any time during the first two years of the strategic alliance. Consequently, the strategic alliance agreement is conditional upon the approval by Arcam’s shareholders at an Arcam General Meeting. The details of the financing arrangement will be described in a separate notice to the General Meeting of Arcam AB.